PRLD

3.2001.69%
BD

Bryant David Lim

CFO, Chief Legal Officer & Corporate Secretary

Mr. Bryant David Lim J.D. is Chairman of the Board of Life Sciences Pennsylvania. Mr. Lim serves as Chief Legal Officer at Prelude Therapeutics Incorporated since February 2023 and served its Corporate Secretary and also served as its Interim Chief Financial Officer since April 8, 2024 until February 3, 2025 and also serves as CFO Since February 3, 2025. He had been General Counsel at Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) since September 11, 2018 until February 17, 2023 and served as its Senior Vice President since September 11, 2018 until September 2022. He served as Company Secretary at Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) since September 11, 2018 until 2022. He served as Chief Business Officer at Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) since September 2018 until February 17, 2023. He joined Idera in September 2018. Mr. Lim served as Vice President, Assistant General Counsel of Incyte Corporation and was its Global Chief Compliance Officer at Incyte Corporation from March 2014 to September 2018. Prior to Incyte, Mr. Lim held roles of increasing responsibility at ViroPharma Incorporated from January 2009 until its acquisition by Shire Plc in January 2014, Merck & Co., Inc. and Morgan, Lewis & Bockius, LLP. Mr. Lim also serves on the Board of Directors of Life Sciences of Pennsylvania. He began his legal career as a law clerk for a federal judge. Mr. Lim received his J. D. from Villanova University School of Law, where he serves on its adjunct faculty, where he teaches about the Law of Drugs and Biologics. Mr. Lim received his Bachelor of Arts from University of Rochester.

Positions